Essential CNS Drug Development
- Editors:
- Amir Kalali, University of California, San Diego
- Sheldon Preskorn, University of Kansas School of Medicine
- Joseph Kwentus, University of Mississippi
- Stephen M. Stahl, University of California, San Diego
- Date Published: June 2012
- availability: Available
- format: Hardback
- isbn: 9780521766067
Hardback
Other available formats:
eBook
Looking for an inspection copy?
This title is not currently available on inspection
-
Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.
Read more- Describes the entire process of drug development, including detailed coverage of each phase of the pre-clinical research and clinical trials
- Provides both detailed content for experienced drug developers and an accessible overview of use to newcomers to the field
- Previews future trends in CNS drug development, from expert authors and editors who work at the cutting edge of their disciplines
Reviews & endorsements
'The experienced authors admirably describe the art and skills of managing the constraints of recruitment criteria, prioritising participant welfare, and balancing budgetary concerns … The volume can be recommended for the libraries of senior investigators who are training the next generation as a stimulus in the supervisory process. The text also offers a springboard for discussions among policy makers themselves, hopefully promoting an insight that they are overdue in their effort to overhaul a system nearly imploding under ponderous, regulatory, protectionistic, and, unfortunately, often minimally scientific burdens of multiple financial and other interests. The brief format is highly readable, more concise than comprehensive in scope, providing more of an overview of the issues than would be expected from a formal reference text … Overall, the editors offer a timely discussion of many strengths and weaknesses of a highly regulated and cumbersome process.' Ronald M. Salomon, Journal of Clinical Psychiatry
Customer reviews
Not yet reviewed
Be the first to review
Review was not posted due to profanity
×Product details
- Date Published: June 2012
- format: Hardback
- isbn: 9780521766067
- length: 215 pages
- dimensions: 240 x 161 x 15 mm
- weight: 0.52kg
- contains: 27 b/w illus. 5 colour illus. 23 tables
- availability: Available
Table of Contents
Preface
1. History of CNS drug development Sheldon H. Preskorn
2. Regulatory issues Gwen L. Zornberg
3. Pre-clinical development Alan J. Cross and Frank D. Yocca
4. Phase I trials: from traditional to newer approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn
5. Phase II development and the path to personalized medicine in CNS disease Douglas E. Feltner and Kenneth R. Evans
6. CNS drug development – Phase III Judith Dunn, Penny Randall and Amir Kalali
7. Statistics issues relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs
8. Clinical trials management at company level Nuala Murphy
9. Clinical trials management at the site level Joseph Kwentus
10. Medical writing for CNS indications Ginette Nachman
11. Dissemination of clinical trial information: multiple audiences, multiple formats Leslie Citrome
12. The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date Philip D. Harvey and Richard S. E. Keefe
13. Leveraging disruptive technologies to drive innovation in CNS clinical drug development Penny Randall, Judith Dunn and Amir Kalali
Index.
Related Books
related journals
also by this author
Sorry, this resource is locked
Please register or sign in to request access. If you are having problems accessing these resources please email [email protected]
Register Sign in» Proceed
You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.
Continue ×Are you sure you want to delete your account?
This cannot be undone.
Thank you for your feedback which will help us improve our service.
If you requested a response, we will make sure to get back to you shortly.
×